72
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Modeling Disease Severity in Multiple Sclerosis Using Electronic Health Records

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To optimally leverage the scalability and unique features of the electronic health records (EHR) for research that would ultimately improve patient care, we need to accurately identify patients and extract clinically meaningful measures. Using multiple sclerosis (MS) as a proof of principle, we showcased how to leverage routinely collected EHR data to identify patients with a complex neurological disorder and derive an important surrogate measure of disease severity heretofore only available in research settings.

          Methods

          In a cross-sectional observational study, 5,495 MS patients were identified from the EHR systems of two major referral hospitals using an algorithm that includes codified and narrative information extracted using natural language processing. In the subset of patients who receive neurological care at a MS Center where disease measures have been collected, we used routinely collected EHR data to extract two aggregate indicators of MS severity of clinical relevance multiple sclerosis severity score (MSSS) and brain parenchymal fraction (BPF, a measure of whole brain volume).

          Results

          The EHR algorithm that identifies MS patients has an area under the curve of 0.958, 83% sensitivity, 92% positive predictive value, and 89% negative predictive value when a 95% specificity threshold is used. The correlation between EHR-derived and true MSSS has a mean R 2 = 0.38±0.05, and that between EHR-derived and true BPF has a mean R 2 = 0.22±0.08. To illustrate its clinical relevance, derived MSSS captures the expected difference in disease severity between relapsing-remitting and progressive MS patients after adjusting for sex, age of symptom onset and disease duration (p = 1.56×10 −12).

          Conclusion

          Incorporation of sophisticated codified and narrative EHR data accurately identifies MS patients and provides estimation of a well-accepted indicator of MS severity that is widely used in research settings but not part of the routine medical records. Similar approaches could be applied to other complex neurological disorders.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2).

          Informatics for Integrating Biology and the Bedside (i2b2) is one of seven projects sponsored by the NIH Roadmap National Centers for Biomedical Computing (http://www.ncbcs.org). Its mission is to provide clinical investigators with the tools necessary to integrate medical record and clinical research data in the genomics age, a software suite to construct and integrate the modern clinical research chart. i2b2 software may be used by an enterprise's research community to find sets of interesting patients from electronic patient medical record data, while preserving patient privacy through a query tool interface. Project-specific mini-databases ("data marts") can be created from these sets to make highly detailed data available on these specific patients to the investigators on the i2b2 platform, as reviewed and restricted by the Institutional Review Board. The current version of this software has been released into the public domain and is available at the URL: http://www.i2b2.org/software.
            • Record: found
            • Abstract: found
            • Article: not found

            Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

            There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.
              • Record: found
              • Abstract: found
              • Article: not found

              The measurement and clinical relevance of brain atrophy in multiple sclerosis.

              Brain atrophy has emerged as a clinically relevant component of disease progression in multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive and reproducible manner by MRI. Clinical studies have shown that brain atrophy begins early in the disease course. The increasing amount of data linking brain atrophy to clinical impairments suggest that irreversible tissue destruction is an important determinant of disease progression to a greater extent than can be explained by conventional lesion assessments. In this review, we will summarise the proposed mechanisms contributing to brain atrophy in patients with multiple sclerosis. We will critically discuss the wide range of MRI-based methods used to quantify regional and whole-brain-volume loss. Based on a review of current information, we will summarise the rate of atrophy among phenotypes for multiple sclerosis, the clinical relevance of brain atrophy, and the effect of disease-modifying treatments on its progression.

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2013
                11 November 2013
                : 8
                : 11
                : e78927
                Affiliations
                [1 ]Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
                [2 ]Harvard Medical School, Boston, Massachusetts, United States of America
                [3 ]Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
                [4 ]Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
                [5 ]Research Computing and Informatics Service, Partners HealthCare, Charlestown, Massachusetts, United States of America
                [6 ]Department of Pediatrics, Boston Children’s Hospital, Boston, Massachusetts, United States of America
                [7 ]Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
                [8 ]Center for System Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
                [9 ]Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
                [10 ]Laboratory for Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
                [11 ]Laboratory of Computer Science, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
                [12 ]Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America
                [13 ]i2b2/National Center for Biomedical Computing, Partners HealthCare, Boston, Massachusetts, United States of America
                University of Maryland, College Park, United States of America
                Author notes

                Competing Interests: GKS and PC, are on the Advisory Board of Wired Informatics, LLC, which provides services and products for clinical natural language processing (NLP) applications. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: ZX PLD. Performed the experiments: ZX RMB AC VSG SNM PJC GKS TC HLW. Analyzed the data: ZX ES LBC SC TC. Contributed reagents/materials/analysis tools: ZX PJC GKS. Wrote the paper: ZX. Critical Revision of the manuscript: ZX KPL SYS ANA PS EWK SEC RMP ISK PLD.

                Article
                PONE-D-13-20838
                10.1371/journal.pone.0078927
                3823928
                24244385
                d92be242-ba13-49c5-936c-b76a7d7d0015
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 21 May 2013
                : 17 September 2013
                Page count
                Pages: 9
                Funding
                The study was supported by NIH U54-LM008748 from the National Institutes of Health Office of the Director, National Library of Medicine and the National Institute of General Medical Sciences. ZX was a recipient of the Clinician Scientist Development Award from the National Multiple Sclerosis Society and the American Academy of Neurology and is supported by NIH K08-NS079493. KPL is supported by NIH K08 AR 060257 and the Harold and Duval Bowen Fund. ANA is supported by NIH K23 DK097142. PLD is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article

                Related Documents Log